Neurotrope to Present Additional Findings from Bryostatin Phase 2 Trial in Advanced Alzheimer's Disease

NEW YORK, Dec. 19, 2017 /PRNewswire/ -- Neurotrope, Inc. (NASDAQ: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease (AD), today announced that it will present additional clinical findings from its Phase 2 bryostatin trial in patients with advanced AD in a keynote presentation at the Sachs' Neuroscience Innovation Forum on January 7 in San Francisco.

Daniel Alkon, MD, President and Chief Scientific Officer of Neurotrope, will also be presenting at the 10^th Annual Biotech Showcase Conference taking place in San Francisco from January 8–10, 2018.

Details of the Sachs' Neuroscience Innovation Forum are as follows:

Details of the Company presentation at the 10^th Annual Biotech Showcase Conference are as follows:

"We look forward to sharing the additional findings from our Phase 2 bryostatin trial with our scientific and industry peers," said Daniel Alkon, MD, President and Chief Scientific Officer at Neurotrope. "Based on our data analysis, we now have greater insights into the potential clinical benefits of bryostatin that will guide our ongoing development of this agent for Alzheimer's disease and other neurodegenerative disorders."

About Sachs Neuroscience Innovation Forum

The Neuroscience Innovation Forum for BD&L and Investment in Therapeutics and Technology program will cover BioPartnering for CNS, with industry keynotes and panels on AD, PD, Neuropsychiatry and Pain Management. Moreover there are panels on innovation in NeuroTech covering banking, device, diagnostics and software. The target audience are buy and sell side analysts from investment banks and funds and partnering executives from pharma and medtech companies. Around 200 delegates and 20 company presentations by established and emerging companies are anticipated at this year's forum.

About Bryostatin

Bryostatin-1 is a protein kinase C epsilon (PKCɛ) activator that works through synaptic growth factors, as well as anti-amyloid and anti-tangle signaling pathways in the brain. It has been shown in preclinical efficacy studies to induce the growth of mature synapses in the brain and prevent neuronal death. Thus, Bryostatin-1 introduces a fundamentally different biological mechanism of action with the potential for longer lasting effects than the other currently available therapies. Bryostatin-1 is the first PKCε modulator to be tested in a phase 2 clinical study for patients suffering from advanced AD — a difficult to treat population.  

The rationale for researching this novel mechanism in AD results from in vitro and in vivo models of AD demonstrating that modulation of PKCε by Bryostatin-1 enhances synaptogenesis and prevents neuronal death. As synaptic loss is tightly correlated with cognitive impairment in AD, this attribute of the molecule made bryostatin an intriguing candidate for additional investigation in dementia. Furthermore, preclinical studies also demonstrated bryostatin reduces toxic Aß levels, prevents plaque formation, inhibits tau phosphorylation, and enhances cognition. Thus, the multimodal effects of this first PKCε modulator offer a potential new mechanism to study in AD with the ultimate goal to slow or prevent the progression of disease.  

About Neurotrope

Neurotrope is at the forefront of developing a new approach to combating AD and other neurodegenerative diseases. The Company's world-class science offers the potential to realize a paradigm shift to overcome one of today's most challenging clinical problems — finding a way to slow or even prevent the progression of AD.

In addition to the Company's Phase 2 trial of bryostatin-1 in advanced AD, Neurotrope has also conducted preclinical studies of bryostatin as a potential treatment for Fragile X Syndrome, Niemann-Pick Type C disease and Rett Syndrome—three rare genetic diseases for which only symptomatic treatments are currently available. The FDA has granted Orphan Drug Designation to Neurotrope for Bryostatin-1 as a treatment for Fragile X Syndrome. Bryostatin-1 has already undergone testing in more than 1,500 people in cancer studies, thus creating a large safety data base that will further inform clinical trial designs in AD.

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. These forward-looking statements include statements regarding the Phase 2 study and further studies, and continued development of use of Bryostatin-1 for Alzheimer's dementia and other cognitive diseases. Such forward-looking statements are subject to risks and uncertainties and other influences, many of which the Company has no control over. These statements are subject to the risk that further analyses of the Phase 2 data may lead to different interpretations of the data than the analyses conducted to date and/or may identify important implications of the Phase 2 data that are not reflected in these statements. Clinical trial data are subject to differing interpretations, and regulatory agencies, medical and scientific experts and others may not share the Company's views of the Phase 2 data. There can be no assurance that the clinical program for Bryostatin-1 will be successful in demonstrating safety and/or efficacy that we will not encounter problems or delays in clinical development, or that Bryostatin-1 will ever receive regulatory approval or be successfully commercialized. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Additional factors that may influence or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain adequate financing, the significant length of time associated with drug development and related insufficient cash flows and resulting illiquidity, the Company's patent portfolio, the Company's inability to expand the Company's business, significant government regulation of pharmaceuticals and the healthcare industry, lack of product diversification, availability of the Company's raw materials, existing or increased competition, stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC, including the Company's Annual Report on Form 10-K for the year ended December 31, 2016 and on Form 10-Q for the quarter ending September 30, 2017. The Company does not undertake to update these forward-looking statements.

Please visit www.neurotropebioscience.com for further information.

Contact information:

Investors
Jeffrey Benison, Director of Corporate Communications
Neurotrope Bioscience, Inc.
973.242.0005 Ext. 101 
[email protected]

Media
James Heins
Senior Vice President
ICR Healthcare
203.856.2121 
[email protected]

SOURCE Neurotrope, Inc.

Related Links

http://www.neurotropebioscience.com